artesunic acid has been researched along with B-Cell Lymphoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, B; Dillard, P; Holien, T; Inderberg, EM; Lingjærde, OC; Myhre, MR; Myklebust, JH; Oksvold, MP; Smeland, EB; Steen, CB; Sundan, A; Theodossiou, TA; Våtsveen, TK; Wälchli, S | 1 |
| Bonavida, B; Efferth, T; Gdynia, G; Roth, W; Sieber, S | 1 |
2 other study(ies) available for artesunic acid and B-Cell Lymphoma
| Article | Year |
|---|---|
Artesunate shows potent anti-tumor activity in B-cell lymphoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Artesunate; Cell Line, Tumor; Cell Proliferation; Glycolysis; Humans; Lymphoma, B-Cell; Mice; Transcriptome; Unfolded Protein Response; Xenograft Model Antitumor Assays | 2018 |
Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antimalarials; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Artemisinins; Artesunate; BH3 Interacting Domain Death Agonist Protein; Catalase; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; fas Receptor; Glutathione S-Transferase pi; Humans; Lymphoma, B-Cell; Membrane Potential, Mitochondrial; Mitochondria; Oxidative Stress; Reactive Oxygen Species; Rituximab; Sp1 Transcription Factor; Superoxide Dismutase; YY1 Transcription Factor | 2009 |